Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Apr;17(4):707–714. doi: 10.1128/aac.17.4.707

Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity.

M Barza, M W Lauermann, F P Tally, S L Gorbach
PMCID: PMC283857  PMID: 6994638

Abstract

The toxicity of netilmicin was compared with that of amikacin in a randomized, prospective trial in 90 adults with a variety of serious gram-negative infections. There was no instance of antibiotic-related nephrotoxicity in the group given amikacin and only one instance in the group given netilmicin. Cochlear toxicity, as measured by a change in audiogram, occurred in 4/14 (28.5%) of the amikacin recipients and 3/19 (15.8%) of the netilmicin recipients. Vestibular toxicity, as determined by a change in ice-water calorics, was noted in 3/16 (19%) of the amikacin-treated patients and 0/15 of the netilmicin-treated individuals. Despite the trend toward lesser ototoxicity with netilmicin, the differences between the drugs were not statistically significant. There was, however, a significant association between male sex and the development of ototoxicity. Although many patients could not be evaluated for efficacy, there did not appear to be any difference in the therapeutic activity of the two drugs.

Full text

PDF
707

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Pinn V., Tanguay P., Murray T. Nephrotoxicity of newer cephalosporins and aminoglycosides alone and in combination in a rat model. J Antimicrob Chemother. 1978 May;4 (Suppl A):59–68. doi: 10.1093/jac/4.suppl_a.59. [DOI] [PubMed] [Google Scholar]
  2. Becker G. D. The screening value of monothermal caloric tests. Laryngoscope. 1979 Feb;89(2 Pt 1):311–314. doi: 10.1288/00005537-197902000-00015. [DOI] [PubMed] [Google Scholar]
  3. Black R. E., Lau W. K., Weinstein R. J., Young L. S., Hewitt W. L. Ototoxicity of amikacin. Antimicrob Agents Chemother. 1976 Jun;9(6):956–961. doi: 10.1128/aac.9.6.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brummett R. E., Fox K. E., Brown R. T., Himes D. L. Comparative ototoxic liability of netilmicin and gentamicin. Arch Otolaryngol. 1978 Oct;104(10):579–584. doi: 10.1001/archotol.1978.00790100033007. [DOI] [PubMed] [Google Scholar]
  5. Buckwold F. J., Ronald A. R., Lank B., Thompson L., Fox L., Harding G. K. Clinical efficacy and toxicity of netilmicin in the treatment of gram-negative infections. Can Med Assoc J. 1979 Jan 20;120(2):161–167. [PMC free article] [PubMed] [Google Scholar]
  6. Fee W. E., Jr, Vierra V., Lathrop G. R. Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report. J Antimicrob Chemother. 1978 May;4 (Suppl A):31–36. doi: 10.1093/jac/4.suppl_a.31. [DOI] [PubMed] [Google Scholar]
  7. Jackson G. G., Arcieri G. Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis. 1971 Dec;124 (Suppl):S130–S137. doi: 10.1093/infdis/124.supplement_1.s130. [DOI] [PubMed] [Google Scholar]
  8. Keating M. J., Bodey G. P., Valdivieso M., Rodriguez V. A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) 1979 Mar;58(2):159–170. doi: 10.1097/00005792-197903000-00004. [DOI] [PubMed] [Google Scholar]
  9. Lane A. Z., Wright G. E., Blair D. C. Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States. Am J Med. 1977 Jun;62(6):911–918. doi: 10.1016/0002-9343(77)90660-x. [DOI] [PubMed] [Google Scholar]
  10. Love L. J., Schimpff S. C., Hahn D. M., Young V. M., Standiford H. C., Bender J. F., Fortner C. L., Wiernik P. H. Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med. 1979 Apr;66(4):603–610. doi: 10.1016/0002-9343(79)91170-7. [DOI] [PubMed] [Google Scholar]
  11. Luft F. C., Yum M. N., Kleit S. A. Comparative nephrotoxicities of netilmicin and gentamicin in rats. Antimicrob Agents Chemother. 1976 Nov;10(5):845–849. doi: 10.1128/aac.10.5.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maigaard S., Frimodt-Möller N., Madsen P. O. Comparison of netilmicin and amikacin in treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 1978 Oct;14(4):544–548. doi: 10.1128/aac.14.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Miller G. H., Arcieri G., Weinstein M. J., Waitz J. A. Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic. Antimicrob Agents Chemother. 1976 Nov;10(5):827–836. doi: 10.1128/aac.10.5.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neu H. C., Bendush C. L. Ototoxicity of tobramycin: a clinical overview. J Infect Dis. 1976 Aug;134 (Suppl):S206–S218. doi: 10.1093/infdis/134.supplement_1.s206. [DOI] [PubMed] [Google Scholar]
  15. Price K. E., DeFuria M. D., Pursiano T. A. Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates. J Infect Dis. 1976 Nov;134(Suppl):S249–S261. doi: 10.1093/infdis/135.supplement_2.s249. [DOI] [PubMed] [Google Scholar]
  16. Smith C. R., Baughman K. L., Edwards C. Q., Rogers J. F., Lietman P. S. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977 Feb 17;296(7):349–353. doi: 10.1056/NEJM197702172960701. [DOI] [PubMed] [Google Scholar]
  17. Snydman D. R., Tally F. P., Landesman S. H., Barza M., Gorbach S. L. Netilmicin in gram-negative bacterial infections. Antimicrob Agents Chemother. 1979 Jan;15(1):50–54. doi: 10.1128/aac.15.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES